248
Participants
Start Date
May 31, 2012
Primary Completion Date
May 31, 2013
Study Completion Date
July 31, 2013
MPSK3169A
Dose regimen A, repeating subcutaneous injections every 4 weeks
MPSK3169A
Dose regimen E, repeating subcutaneous injections every 4 weeks
MPSK3169A
Dose regimen D, repeating subcutaneous injections every 4 weeks
MPSK3169A
Dose regimen C, repeating subcutaneous injections every 4 weeks
MPSK3169A
Dose regimen B, repeating subcutaneous injections every 4 weeks
Placebo
Repeating subcutaneous injections of placebo every 4 weeks
Auckland
Hamar
Elverum
Komárom
Tauranga
Sandnes
Nyíregyháza
Nelson
Cape Town
Cape Town
Christchurch
Nagykanizsa
Sopron
Berlin
Rochester
Bethesda
Baltimore
Richmond
Knoxville
Wilmington
Spartanburg
Mt. Pleasant
Greer
Ponte Verde
Jacksonville
Bristol
Cincinnati
Cincinnati
Springdale
Indianapolis
Jičícin
Cologne
Iowa City
Rapid City
Fargo
St Louis
Oklahoma City
Tulsa
Dallas
Dallas
Houston
Boerne
Boise
Goodyear
Spring Valley
Wildomar
Walnut Creek
Carmichael
Wenatchee
Auburn
Mount Pearl
St. John's
Sarnia
Toronto
Woodstock
Montreal
Montreal
Saint-Jérôme
Sainte-Foy
Trois-Rivières
Hodonín
Mariánské Lázně
Ostrava - Poruba
Rakovník
Auckland
Oslo
Oslo
Bardejov
Bratislava
Prešov
Rimavská Sobota
Centurion
Pretoria
Lead Sponsor
Genentech, Inc.
INDUSTRY